Epiphany Biosciences, Inc. – Product Pipeline Review – H2 2011

Document Sample
Epiphany Biosciences, Inc. – Product Pipeline Review – H2 2011 Powered By Docstoc
					Epiphany Biosciences, Inc. – Product Pipeline Review




 Epiphany Biosciences, Inc. – Product Pipeline Review
                     – H2 2011


                                                                                            Reference Code: GMDHC02136CDB

                                                                                                   Publication Date: DEC 2011




Epiphany Biosciences, Inc. – Product Pipeline Review – H2 2011
                                                                                          GMDHC02136CDB / Published DEC 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Epiphany Biosciences, Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Epiphany Biosciences, Inc. Snapshot ................................................................................................................................................ 5
    Epiphany Biosciences, Inc. Overview ............................................................................................................................................ 5
    Key Information ............................................................................................................................................................................. 5
    Key Facts....................................................................................................................................................................................... 5
Epiphany Biosciences, Inc. – Research and Development Overview ................................................................................................ 6
    Key Therapeutic Areas .................................................................................................................................................................. 6
Epiphany Biosciences, Inc. – Pipeline Review ................................................................................................................................... 8
    Pipeline Products by Stage of Development ................................................................................................................................. 8
    Pipeline Products – Monotherapy ................................................................................................................................................. 9
Epiphany Biosciences, Inc. – Pipeline Products Glance .................................................................................................................. 10
    Epiphany Biosciences, Inc. Clinical Stage Pipeline Products ...................................................................................................... 10
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 10
    Epiphany Biosciences, Inc. – Early Stage Pipeline Products ...................................................................................................... 11
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 11
        Discovery Products/Combination Treatment Modalities.......................................................................................................... 12
Epiphany Biosciences, Inc. – Drug Profiles ...................................................................................................................................... 13
    EPB-200 ...................................................................................................................................................................................... 13
        Product Description................................................................................................................................................................. 13
        Mechanism of Action ............................................................................................................................................................... 13
        R&D Progress ......................................................................................................................................................................... 13
    EPB-348 ...................................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    EPB-415 ...................................................................................................................................................................................... 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
    EPB-500 ...................................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
Epiphany Biosciences, Inc. – Pipeline Analysis................................................................................................................................ 17
    Epiphany Biosciences, Inc. – Pipeline Products by Therapeutic Class ....................................................................................... 17
    Epiphany Biosciences, Inc. - Pipeline Products By Target .......................................................................................................... 18
    Epiphany Biosciences, Inc. – Pipeline Products by Route of Administration ............................................................................... 19
    Epiphany Biosciences, Inc. – Pipeline Products by Molecule Type ............................................................................................. 20
Epiphany Biosciences, Inc. - Dormant Projects ................................................................................................................................ 21
Epiphany Biosciences, Inc. – Locations And Subsidiaries ............................................................................................................... 22



Epiphany Biosciences, Inc. – Product Pipeline Review – H2 2011
                                                                                                                                 GMDHC02136CDB / Published DEC 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
Epiphany Biosciences, Inc. – Product Pipeline Review



    Head Office.................................................................................................................................................................................. 22
Company's Recent Developments ................................................................................................................................................... 23
    Epiphany Biosciences, Inc., Recent Developments..................................................................................................................... 23
         Mar 24, 2009: Epiphany Biosciences Plans On Filing An IND For Valomaciclovir (MIV-606) Targeting MS .......................... 23
         Nov 18, 2009: Epiphany Announces Positive Results Of Its Drug Candidate Valomaciclovir From Its Phase 2b Trial In
         Shingles .................................................................................................................................................................................. 23
         Dec 10, 2007: Epiphany Biosciences Initiates Phase II Study Of Valomaciclovir (MIV-606, EPB-348) .................................. 24
         Sep 09, 2008: Epiphany Biosciences Announces To Continue Phase 2 shingles Study After Interim Analysis ..................... 25
         Nov 08, 2007: Epiphany Biosciences Has Initiated Enrollment In Shingles Study With Valomaciclovir (MIV-606, EBP-348)
         Licensed From Medivir .....................................................................
				
DOCUMENT INFO
Description: Epiphany Biosciences, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Epiphany Biosciences, Inc. - Product Pipeline Review - H2 2011” provides data on the Epiphany Biosciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Epiphany Biosciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Epiphany Biosciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Epiphany Biosciences, Inc. - Brief Epiphany Biosciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Epiphany Biosciences, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Epiphany Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Epiphany Biosciences, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Epiphany Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Epiphany Biosciences, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Epiphany Biosciences, Inc.’s R&D portf
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries